| Budget Amount *help |
¥47,320,000 (Direct Cost: ¥36,400,000、Indirect Cost: ¥10,920,000)
Fiscal Year 2011: ¥12,740,000 (Direct Cost: ¥9,800,000、Indirect Cost: ¥2,940,000)
Fiscal Year 2010: ¥14,560,000 (Direct Cost: ¥11,200,000、Indirect Cost: ¥3,360,000)
Fiscal Year 2009: ¥20,020,000 (Direct Cost: ¥15,400,000、Indirect Cost: ¥4,620,000)
|
|---|
| Research Abstract |
We previously developed a hepatitis B virus (HBV) surface antigen L protein particle [bio-nanocapsule (BNC)] as a nonviral DDS nanocarrier. Intravenously injected BNCs were shown to avoid clearance by RES (reticuloendothelial system)-rich organs and accumulate in target tissues. In this study, since the surface modification with albumins is known to prolong the circulating half-life of nanomedicines, we demonstrated that the polymerized albumin receptor (PAR) of BNCs contributes to RES evasion in mouse liver,strongly suggesting that BNCs, as well as HBV, harbor an innate RES evasion mechanism. Therefore, the surface modification with PAR peptides could be an alternative strategy forimproving pharmacodynamics and pharmacokinetics of forthcoming nanomedicines.
|
